Pascal Burtin
Overview
Explore the profile of Pascal Burtin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
346
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tarabay A, Boileve A, Smolenschi C, Antoun L, Valery M, Fuerea A, et al.
Biomedicines
. 2023 Sep;
11(9).
PMID: 37761010
Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of death by cancer worldwide. Mostly diagnosed with locally advanced or metastatic disease, patients lack treatment options. Gene alterations (GAs)...
2.
Cheminel L, Lupu A, Wallenhorst T, Lepilliez V, Leblanc S, Albouys J, et al.
Am J Gastroenterol
. 2023 Sep;
119(2):378-381.
PMID: 37734341
Introduction: When initial resection of rectal neuroendocrine tumors (r-NETs) is not R0, persistence of local residue could lead to disease recurrence. This study aimed to evaluate the interest of systematic...
3.
Kanaan C, Cotteret S, Khneisser P, Soufan R, Bani M, Burtin P, et al.
Int J Surg Pathol
. 2022 Mar;
30(7):823-827.
PMID: 35257620
"Juvenile-like (hyperplastic/inflammatory) mucosal polyp" is a term proposed for rare benign mesenchymal lesions of the gastro-intestinal tract so far reported only in patients with type 1 neurofibromatosis (NF1). We report...
4.
Bourdais R, Achkar S, Espenel S, Bockel S, Chauffert-Yvart L, de Mellis F, et al.
J Contemp Brachytherapy
. 2021 Jun;
13(3):263-272.
PMID: 34122565
Purpose: To examine clinical outcomes and quality of life of patients with anal squamous cell carcinoma treated with interstitial pulsed-dose-rate brachytherapy (PDR-BT) with a boost to residual tumor after external...
5.
Levy A, Wagner A, Chargari C, Moehler M, Verheij M, Durand-Labrunie J, et al.
Eur J Cancer
. 2020 Jun;
135:103-112.
PMID: 32563014
Malignant dysphagia is the most common symptom in advanced oesogastric cancers patients. Relief of dysphagia allows quality of life improvement, nutritional replenishment and potentially improves prognosis. Chemotherapy alone is effective...
6.
Benhaim L, Faron M, Hadoux J, Gelli M, Sourrouille I, Burtin P, et al.
Neuroendocrinology
. 2020 Jun;
111(6):599-608.
PMID: 32512564
Introduction: Peritoneal metastases from neuroendocrine tumors are associated with a bad prognosis. The objective of our study was to evaluate whether surgical resection could lead to prolonged survival in selected...
7.
Kissel M, Chirat E, Annede P, Burtin P, Fumagalli I, Bronsart E, et al.
Brachytherapy
. 2020 May;
19(4):499-509.
PMID: 32444283
Purpose: Esophageal cancer is characterized by its propension to local evolution, which conditions prognosis and quality of life. Brachytherapy may be a therapeutic option for all stages of esophageal cancer....
8.
Karsenti D, Tharsis G, Perrot B, Cattan P, Tordjman G, Venezia F, et al.
Gut
. 2020 Mar;
69(12):2159-2164.
PMID: 32209605
Objective: Endocuff Vision (ECV) is the second generation of a device designed to improve polyp detection. The aim of this study was to evaluate its impact on adenoma detection rate...
9.
Joyon N, Burtin P, Scoazec J
Ann Pathol
. 2020 Jan;
40(1):31-34.
PMID: 31910995
No abstract available.
10.
Hadoux J, Blanchard P, Scoazec J, Burtin P, Planchard D, Malka D, et al.
Neuroendocrinology
. 2019 Oct;
111(1-2):139-145.
PMID: 31639792
Background: Cancer survivors have a 14% increased risk of developing a malignancy compared with the general population. Second radiation-induced malignancies with different histologies have been described in different organs. Based...